Table 1.
Demographic and clinical characteristics, laboratory findings, treatments, and complications of patients during the acute COVID-19 episode.
| Patients (N = 113) | |
|---|---|
| Sex (N;%) | |
| Man | 79 (69.9) |
| Woman | 34 (30.1) |
| Age, years (median; IQR) | 64 (54–72) |
| Race (N;%) | |
| Asiatic | 1 (0.9) |
| Caucasian | 80 (70.8) |
| Latin | 26 (23.0) |
| Black | 1 (0.9) |
| Other | 5 (4.4) |
| BMI, Kg/m2(median; IQR) | 29.3 (26.2–32.3) |
| Smoking (N;%) | |
| Smoker | 3 (2.7) |
| Former smoker | 35 (31.0) |
| Nonsmoker | 75 (66.4) |
| Barthel Index score (mean; SD) | 99 (4.1) |
| Comorbidities (N;%) | |
| Hypertension | 57 (50.4) |
| Diabetes mellitus | 30 (26.5) |
| Dyslipidemia | 60 (53.1) |
| Atrial fibrillation | 8 (7.1) |
| Heart failure | 3 (2.7) |
| Moderate-severe chronic kidney disease (CKD) 1 | 3 (2.7) |
| Chronic respiratory disease | 29 (25.7) |
| COPD | 7/29 (24.1) |
| Asthma | 10/29 (34.5) |
| OSAS | 16/29 (55.2) |
| Interstitial lung disease | 1/29 (3.5) |
| Peripheral vascular disease | 8 (7.1) |
| Stroke | 3 (2.7) |
| Solid malignancy | 10 (8.9) |
| Non metastatic neoplasia | 10/10 (100) |
| Metastatic neoplasia | 0 (0) |
| HIV infection | 2 (1.8) |
| Other immunosuppression's 2 | 2 (2.7) |
| Charlson index score (mean; SD) | 1.05 (1.29) |
| Charlson index score ≤2 points (N;%) | 100 (88.5) |
| Charlson index score >2 points (N;%) | 13 (11.5) |
| Symptoms of COVID-19 (N;%) | |
| Days of symptoms upon admission (median; IQR) | 7(5-10) |
| Dyspnea | 113 (100) |
| Cough | 91 (80.5) |
| Rhinorrhea | 8 (7.1) |
| Anosmia | 16 (14.2) |
| Ageusia | 19 (16.8) |
| Odynophagia | 8 (7.1) |
| Fever | 98 (86.7) |
| Diarrhea | 27 (23.9) |
| Sickness | 20 (17.7) |
| Vomiting | 11 (9.7) |
| Asthenia | 60 (53.1) |
| Anorexia | 35 (31.0) |
| Headache | 20 (17.7) |
| Arthromyalgia | 48 (42.5) |
| Chest pain | 18 (15.9) |
| Abdominal pain | 9 (8.0) |
| Delirium | 4 (3.5) |
| Laboratory findings (median, IQR) | |
| Maximum CRP, mg/L (median, IQR) | 198 (149–295) |
| Maximum LDH, UI/L (median, IQR) | 435 (345–548) |
| Maximum d-dimer, ng/ml (median, IQR) | 2.900 (1.780 −7.220) |
| Minimal lymphocyte count, /mm3 | 680 (465–855) |
| Treatments (N;%) | |
| Lopinavir/Ritonavir | 9 (8.0) |
| Beta interferon | 3 (2.7) |
| Hydroxychloroquine | 108 (95.6) |
| Tocilizumab | 47 (41.6) |
| Immunoglobulins | 1 (0.9) |
| Corticosteroids | 76 (67.3) |
| Inhaled corticosteroids | 13 (11.5) |
| LMWH | 109 (96.5) |
| Antibiotics | 113 (100) |
| Azithromycin | 96 (85.0) |
| Ampicillin | 6 (5.3) |
| Amoxicillin-Clavulanic | 11 (9.7) |
| Piperacillin-Tazobactam | 18 (15.9) |
| Ceftriaxone | 65 (57.5) |
| Carbapenems | 15 (13.3) |
| Quinolones | 24 (21.3) |
| Daptomycin | 8 (7.1) |
| Linezolid | 15 (13.3) |
| LOS, days (median; IQR) | 23 (13.0–39.0) |
| ICU admission (N;%) | 42 (37.2) |
| Length of ICU stay, days (median; IQR) | 18 (12.8–34.5) |
| Orotracheal intubation and mechanic ventilation | 36/42 (85.7) |
| Non-invasive mechanic ventilation | 17/42 (40.5) |
| Complications (N;%) | |
| Ventilated-associated pneumonia | 13/36 (36.1) |
| Nosocomial tracheobronchitis | 13 (11.5) |
| Heart failure | 7 (6.2) |
| Arrhythmia | 12 (10.6) |
| Stroke | 1 (0.9) |
| Acute coronary syndrome | 3 (2.7) |
| PE | 16 (14.2) |
| Sepsis | 10 (8.9) |
| Mental status abnormalities | 17 (15.0) |
| Catheter related bacteriemia | 30 (26.5) |
Abbreviations: BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; CRP: Chain polymerase reaction; HIV: Human immunodeficiency virus; ICU: Intensive Care Unit; IQR: Interquartile range; LDH: Lactate dehydrogenase; LMWH: Low molecular weight heparin; LOS: length of hospital stay; OSAS: Obstructive sleep apnea syndrome; PE: pulmonary embolism; SD: Standard deviation.
1
Creatinine ≥265 μmol/L.
2
Solid organ transplantation, Hematopoietic stem cell transplantation, Chemotherapy, corticosteroid treatment (prednisone> 10 mg / day or equivalent) or neutropenia.